Spain · Seed startup

Who invested in Nuage Therapeutics

One round we have observed, with the one investor named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Pharma

Funding summaryUpdated 27 Oct 2026

$13Mraised across 1 round since 2023, from 1 source

Latest round
Seed, $13MMar 2023
Investors
1
See who backed them

The rounds

  1. Mar 2023
    Seed$13M

    Source recorded

Founders and team

From Nuage Therapeutics's own website: 3 founders, 7 on the team.

Mateusz BiesagaFounder and Chief Technology Officer
Denes HniszFounder and Observer
Xavier SalvatellaFounder
  • Stuart HughesChief Executive Officer
  • Olivier CorminboeufSenior Vice President – Head of Drug Discovery
  • Pilar CasadoChief Financial Officer
  • Andri LeonidouHead of BI and Corporate Affairs
  • Blandine GuimetHead of People
  • Julia PiOperations and Communications Manager
  • Vanessa MalierChair of the Board

Everyone who backed them

Sofinnova PartnersVC firm1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Nuage Therapeutics

Who invested in Nuage Therapeutics?

Nuage Therapeutics's investors include Sofinnova Partners.

How much has Nuage Therapeutics raised?

Nuage Therapeutics has raised $13M across 1 round since 2023.

When did Nuage Therapeutics last raise?

Nuage Therapeutics's most recent round was a Seed of $13M in Mar 2023.

What was Nuage Therapeutics's biggest round?

Its most recent round, $13M in Mar 2023, is also its largest on record.

Who backed Nuage Therapeutics first?

Nuage Therapeutics's first round on record, in Mar 2023, was backed by Sofinnova Partners.

What stage is Nuage Therapeutics at?

Nuage Therapeutics's latest named round is a Seed, in Mar 2023.

Where is Nuage Therapeutics based?

Nuage Therapeutics is based in Spain.

Companies like Nuage Therapeutics

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.